About Astrazeneca
Astrazeneca is a company based in Cambridge (United Kingdom) founded in 1913. The company has 94,300 employees as of December 31, 2024. Astrazeneca has completed 23 acquisitions, including Acerta Pharma, Alexion and Amolyt Pharma. Astrazeneca offers products and services including Enhertu and Cardiovascular Medicines. Astrazeneca operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Cambridge, United Kingdom
- Employees 94300 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Astrazeneca Pharma India Limited
-
Annual Revenue
$53.02 B (USD)14.82as on Dec 31, 2024
-
Net Profit
$6.9 B (USD)14.92as on Dec 31, 2024
-
EBITDA
$17.5 B (USD)21.08as on Dec 31, 2024
-
Latest Funding Round
$6.09 M (USD), Post-IPO
Dec 27, 2021
-
Investors
European Union
& 5 more
-
Employee Count
94300
as on Dec 31, 2024
-
Investments & Acquisitions
Acerta Pharma
& 22 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Astrazeneca
Astrazeneca is a publicly listed company on the NSE with ticker symbol ASTRAZEN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Astrazeneca
Astrazeneca offers a comprehensive portfolio of products and services, including Enhertu and Cardiovascular Medicines.
Targets HER2-positive metastatic breast cancer through antibody-drug conjugates.
Addresses heart, renal, and metabolic conditions via innovative research.
People of Astrazeneca
Unlock access to complete
Unlock access to complete
Leadership Team
403 people
Software Development Team
205 people
Product Management Team
76 people
Data Analysis and Operations Team
68 people
Senior Team
67 people
Human Resources and Administration
63 people
Sales and Marketing
54 people
Operations Team
50 people
Unlock access to complete
Funding Insights of Astrazeneca
Investors in Astrazeneca
Astrazeneca has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Cambridge and USAGov.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm for early-stage startups
|
Locked | Locked | Locked | |
|
US tech companies are funded across stages by Columbia Capital.
|
Locked | Locked | Locked | |
|
Investment research services are provided to financial clients by Cambridge.
|
Locked | Locked | Locked |
Investor details for Astrazeneca
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Astrazeneca
Astrazeneca has strategically engaged in corporate development activities, having acquired 23 companies. Notable acquisitions include Acerta Pharma, Alexion and Amolyt Pharma.
Investment portfolio details for Astrazeneca
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops AI models for pathology diagnostics and biomedical image analysis.
|
Locked | Locked | 2024 | Locked | |
|
Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.
|
Locked | Locked | 2020 | Locked | |
|
Therapeutics for cardio-renal diseases, including hypertension treatments, are developed.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Astrazeneca
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Astrazeneca
Detailed financials for Astrazeneca
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Astrazeneca Comparisons
Peer comparison for Astrazeneca
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Astrazeneca
Astrazeneca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Astrazeneca
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Astrazeneca
Complete news archive for Astrazeneca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Astrazeneca
Astrazeneca was founded in 1913 and raised its 1st funding round 98 years after it was founded.
Astrazeneca is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Pascal Soirot is the current CEO of Astrazeneca.
As of Dec 31, 2024, the latest employee count at Astrazeneca is 94,300.
Annual revenue of Astrazeneca is $53.02B as on Dec 31, 2024.
AstraZeneca was established in 1913 and operates as a multinational pharmaceutical and biologics firm headquartered in Cambridge, United Kingdom. Operations span over 100 countries, with a focus on products addressing cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory conditions. The company has grown through mergers and acquisitions, including Cambridge Antibody Technology in 2006 and MedImmune in 2007, achieving annual revenues of 43.85 billion in 2022.
Astrazeneca's top competitors include Merck, Roivant Sciences and AbbVie.
Astrazeneca offers Enhertu and Cardiovascular Medicines.
Yes, Astrazeneca is publicly traded on NSE under the ticker symbol ASTRAZEN.
Astrazeneca has made 23 acquisitions, including Acerta Pharma, Alexion, and Amolyt Pharma.
Astrazeneca has 6 investors. Key investors include European Union, Cambridge, USAGov, Public Health Emergency, and Mission Ventures.
The ticker symbol of Astrazeneca is ASTRAZEN on NSE.